The Development of Antimicrobial A-Aapeptides That Suppress Proinflammatory Immune Responses.

Shruti Padhee,Christina Smith,Haifan Wu,Yaqiong Li,Namitha Manoj,Qiao,Zoya Khan,Chuanhai Cao,Hang Yin,Jianfeng Cai
DOI: https://doi.org/10.1002/cbic.201300709
2014-01-01
Abstract:Herein we describe the development of a new class of antimicrobial and anti-inflammatory peptidomimetics: cyclic lipo-α-AApeptides. They have potent and broad-spectrum antibacterial activity against a range of clinically relevant pathogens, including both multidrug-resistant Gram-positive and Gram-negative bacteria. Fluorescence microscopy suggests that cyclic lipo-α-AApeptides kill bacteria by disrupting bacterial membranes, possibly through a mechanism similar to that of cationic host-defense peptides (HDPs). Furthermore, the cyclic lipo-α-AApeptide can mimic cationic host-defense peptides by antagonizing Toll-like receptor 4 (TLR4) signaling responses and suppressing proinflammatory cytokines such as tumor necrosis factor-α (TNF-α). Our results suggest that by mimicking HDPs, cyclic lipo-α-AApeptides could emerge as a new class of antibiotic agents that directly kill bacteria, as well as novel antiinflammatory agents that act through immunomodulation.
What problem does this paper attempt to address?